Foghorn Therapeutics' revenue estimates downgraded by analys...
Foghorn Therapeutics' revenue estimates downgraded by analysts, expected losses per share increased. The company's slower growth compared to industry peers could be a concern for shareholders.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000185058efc05d71.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment